TPG-Axon Capital

Tarana Wireless, Inc. is a technology company that specializes in researching, developing, and commercializing non-line-of-sight (NLoS) wireless transport solutions. Its flagship product, AbsoluteAir 2, offers advanced wireless transport capabilities with features such as deterministic True NLOS performance, extensive coverage, multi-kilometer range, and high spectral efficiency. The company provides construction-grade installation services and a carrier-class management system that allows operators to configure, monitor, and manage their network nodes effectively. Tarana's solutions are designed to support various applications, including small-cell backhaul, wireless fiber extension, and fixed wireless broadband access. The company serves tier-1 telecommunications operators globally and is headquartered in Milpitas, California, with additional offices in Berkeley, California, and Pune, India. Tarana Wireless was established in 2009 and has made significant advancements in wireless technology, offering lower total cost of ownership and unmatched scalability for its clients.

Singular Genomics is a life science technology company that develops innovative sequencing platforms. Its core product, the Singular Sequencing Engine, powers two integrated solutions: G4 for next-generation sequencing (NGS) markets, offering high accuracy and speed; and PX, which combines single-cell analysis, spatial analysis, genomics, and proteomics in one versatile multi-omics instrument. These products aim to empower researchers and clinicians across diverse fields such as basic biology, oncology, immunology, and more.

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 1993. The company focuses on discovering, designing, and developing innovative therapies for the treatment of diseases, particularly in the fields of autoimmunity and cancer. Merrimack employs a systems biology approach that utilizes multidisciplinary capabilities to create functional and predictive computational models of biological systems, including cell signaling networks. By combining novel therapeutics with diagnostics, the company aims to enhance treatment efficacy and outcomes. Additionally, Merrimack engages in third-party agreements to facilitate the processing and commercialization of its products.

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 1993. The company focuses on discovering, designing, and developing innovative therapies for the treatment of diseases, particularly in the fields of autoimmunity and cancer. Merrimack employs a systems biology approach that utilizes multidisciplinary capabilities to create functional and predictive computational models of biological systems, including cell signaling networks. By combining novel therapeutics with diagnostics, the company aims to enhance treatment efficacy and outcomes. Additionally, Merrimack engages in third-party agreements to facilitate the processing and commercialization of its products.